Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses this evolution of clinical trials, and using genomic methods to direct therapy.
Beth M. Faiman, PhD, MSN, CNP, AOCN, of the Cleveland Clinic, discusses working with patients with multiple myeloma to minimize the toxicity of their treatment and improve their outcomes.
Kieron M. Dunleavy, MD, of the National Cancer Institute, discusses the genomic landscape of aggressive lymphomas and how this is informing therapy decisions.
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the role of checkpoint inhibitors in Hodgkin lymphoma and the efficacy of nivolumab and pembrolizumab.
Fredrick B. Hagemeister, Jr, MD, of the University of Texas MD Anderson Cancer Center, discusses whether rituximab maintenance should be used in indolent lymphomas other than follicular.
Andrew D. Zelenetz, MD, of Memorial Sloan Kettering Cancer Center, discusses the pros and cons of these two regimens, with or without another agent, in diffuse large B-cell lymphoma.
